Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 15 November 2019

Abstract and Keywords

Government-run or -regulated health care systems have adopted complex systems of economic regulation to control pharmaceutical expenditures, which are generally an ad hoc mix of historical policies. There has, however, been a substantial increase in the number of third-party payers using formal cost-effectiveness analysis (CEA) or pharmacoeconomic approaches for assessing the value of drugs, vaccines, and other health technologies to inform decisions about pricing, reimbursement, and use within their health care systems. This article explores the theoretical and practical issues that have arisen in the application of CEA for drugs to resource allocation decisions in health care and in the regulation of pharmaceutical prices and use. It begins by outlining the evolution of CEA from the practice of health technology assessment.

Keywords: economic regulation, drug costs, cost-effectiveness analysis, resource allocation, regulation, drug prices, health technology assessment

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.